ATAGI issues clot advice after first Australian case linked to vaccine
What to look out for in patients presenting with pain after receiving the AstraZeneca COVID-19 vaccine
People who develop severe, persistent headaches or abdominal pain 4-20 days after receiving AstraZeneca’s COVID-19 vaccine should be sent to hospital to investigate potential clotting, the Australian Technical Advisory Group on Immunisation (ATAGI) says.
Australia’s first ‘probable’ case of what’s been dubbed ‘vaccine-induced prothrombotic immune thrombocytopenia’ (VIPIT) was reported on Friday.
The 44-year-old man was admitted to Box Hill Hospital in Melbourne after developing thrombosis in abdominal blood vessels seven days after receiving the AstraZeneca vaccine.
A small number of cases of unusual clotting disorders in patients who had received the viral-vector vaccine have been previously reported in Europe.
